tirzepatide being pulled The FDA says the Zepbound shortage is over. That's rattling the weight loss industry How to Inject Tirzepatide (Zepbound/Mounjaro):

The FDA has received 605 reports of adverse events associated with compounded semaglutide and 545 reports of adverse events associated with compounded tirzepatide (as of July 31, 2025)

Compounded semaglutide is not FDA-approved and is not the same as any branded product

While short-term use under supervision may be tolerated, extended use could pose unknown risks

PMID 25753888

Alisia Chen , Karen Zhao , and Felicia Ceban screened and adjudicated abstracts, selected articles for full-text review, and extracted the data

Activities such as brisk walking, swimming, or cycling are accessible to most people and can be gradually increased as fitness improves